CORTISPORIN (hydrocortisone; neomycin sulfate; polymyxin b sulfate) by Monarch Therapeutics is clinical pharmacology colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. Approved for superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics. First approved in 1975.
Drug data last refreshed 31m ago · AI intelligence enriched 1mo ago
Cortisporin is a fixed-dose combination otic solution containing hydrocortisone (corticosteroid), neomycin sulfate (aminoglycoside antibiotic), and polymyxin B sulfate (polypeptide antibiotic). It treats superficial bacterial infections of the external auditory canal by combining anti-inflammatory action with broad-spectrum bactericidal coverage against gram-positive and gram-negative organisms. The formulation works through dual mechanisms: antibiotics disrupt bacterial cell membranes and protein synthesis, while hydrocortisone suppresses inflammation and associated symptoms.
Product faces imminent loss of exclusivity with moderate competitive pressure (30% intensity); brand teams should anticipate significant portfolio contraction and resource reallocation.
CLINICAL PHARMACOLOGY Colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. Neomycin sulfate is an aminoglycoside antibiotic which inhibits protein synthesis, disrupting the normal cycle of ribosomal function. Hydrocortisone acetate is a…
Worked on CORTISPORIN at Monarch Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Cortisporin offers limited career growth potential due to LOE-approaching status and minimal linked job openings. Professionals joining this franchise should expect a focus on margin defense, cost containment, and transition planning rather than brand-building or market expansion.